Protara Therapeutics Inc (TARA) gains 2.22% for July 21

Equities Staff  |

Protara Therapeutics Inc (NASDAQ: TARA) shares gained 2.22%, or $0.19 per share, to close Wednesday at $8.74. After opening the day at $8.62, shares of Protara fluctuated between $8.85 and $8.54. 27,469 shares traded hands a decrease from their 30 day average of 113,849. Wednesday's activity brought Protara’s market cap to $98,138,016.

Protara is headquartered in New York, New York..

About Protara Therapeutics Inc

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara's portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.

Visit Protara Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Protara Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Protara Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content